The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 101–200 of 1,043
Preventing dementia by preventing stroke: The Berlin Manifesto
Hachinski, V., Einhäupl, K., Ganten, D., Alladi, S., Brayne, C., Stephan, B. C. M., Sweeney, M. D., Zlokovic, B., Iturria‐Medina, Y., Iadecola, C., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.06.001 · Cited by 313
“We can also monitor changes in response to interventions such as antiamyloid antibody infusions [91].”
BackgroundAducanumab: Appropriate Use Recommendations
Cummings, J., Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., & Weiner, M. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.41 · Cited by 316
“The Phase 1B study of aducanumab had encouraging results in patients with MMSE scores of 20-30 (15).”
Self-citationThe amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Brothers, H. M., Gosztyla, M. L., & Robinson, S. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00118 · Cited by 314
“In the Aducanumab trials, the incidence of ARIA was even higher, at 47–55% of participants in the highest dosage group (AlzForum (n.d.-a); DiFrancesco et al., 2015; Sevigny et al., 2016).”
BackgroundRole of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179935 · Cited by 313
Prions, prionoids and protein misfolding disorders
Scheckel, C., & Aguzzi, A. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0011-4 · Cited by 321
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
The identity and function of microglia in neurodegeneration
Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
“…pending NCT02782975 Intravenous Prodromal to Mild AD Accelerated Approval (Chiao et al., 2019; ClinicalTrials.gov, 2019a; b, f; Ferrero et al., 2016; Sevigny et al., 2016) https ://www.fda.gov/dr ugs/news-events-h uman-drugs/fdas-d ecision-approve-n ew-treatment-alzh eimers-disease BIIB037…”
BackgroundAmyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
Villegas, S., Roda, A., Serra-Mir, G., Montoliu-Gaya, L., & Tiessler, L. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.332127 · Cited by 306
“2– q21) (Figure 1C), as well as in the catalytic units of γ-secretase genes, presenilin 1 (Sherrington et al., 1995) (PSEN1, 14q24.”
BackgroundSaltmarche, A. E., Naeser, M. A., Ho, K. F., Hamblin, M. R., & Lim, L. (2017) · Photomedicine and Laser Surgery · doi:10.1089/pho.2016.4227 · Cited by 299
“To our knowledge, this case series is the first completed PBM case series to document significant, cognitive improvement in mild to moderately severe dementia or AD.31”
BackgroundInfluentialJack, C. R., Therneau, T. M., Weigand, S. D., Wiste, H. J., Knopman, D. S., Vemuri, P., Lowe, V. J., Mielke, M. M., Roberts, R. O., Machulda, M. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1971 · Cited by 300
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Cummings, J. (2018) · Clinical and Translational Science · doi:10.1111/cts.12491 · Cited by 298
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
Blennow, K. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0073-9 · Cited by 295
“Furthermore, the Phase1b aducanumab trial showed a doseand time-dependent reduction in brain amyloid plaques as measured by florbetapir PET, but also a high frequency of amyloid-related imaging abnormalities (ARIA) [19].”
BackgroundDhillon, S. (2021) · Drugs · doi:10.1007/s40265-021-01569-z · Cited by 293
“Histological staining of autopsy tissue from patients with Alzheimer’s disease confirmed the binding of aducanumab to amyloid β fibrils [6].”
BackgroundInfluentialChallenges and hopes for Alzheimer’s disease
Tatulian, S. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.016 · Cited by 291
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Resveratrol for Alzheimer's disease
Sawda, C., Moussa, C., & Turner, R. S. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13431 · Cited by 276
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
“The main safety and tolerability concerns were ARIA [51] (NCT01677572).”
BackgroundInfluentialGovindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
“A preliminary study with human aducanumab indicated that the drug was able to reduce fibrillary Aβ load in prodromal and mild AD patients when administered intravenously for one year (once per month) and that this reduction was dose- and time-dependent [440].”
BackgroundInfluentialStereospecific interactions between chiral inorganic nanomaterials and biological systems
Zhao, X., Zang, S.-Q., & Chen, X. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00093k · Cited by 274
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275
Shi, M., Chu, F., Zhu, F., & Zhu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.870517 · Cited by 275
Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases
Schoch, K. M., & Miller, T. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.010 · Cited by 274
“Antibodies targeted against Ab, solanezumab, and aducanumab are currently in clinical trial and reporting efficacy (Sevigny et al., 2016; Siemers et al., 2016), suggesting antibody-mediated therapeutics are on par with ASOs in their clinical application.”
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al‐Tel, T. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 274
“Preclinical studies in transgenic mice demonstrated the ability of aducanumab analog to cross the BBB, recognize its Aβ target and increase the clearance of Aβ plaques.(129) Accordingly, aducanumab completed earlier phases of”
BackgroundMethodTau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272
The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration
Azam, S., Haque, M. E., Balakrishnan, R., Kim, I.-S., & Choi, D.-K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683459 · Cited by 255
“During these events several biochemical character changes sequentially, starting with the activation of pro-caspase (e.g., caspase-9) at the cytoplasm which then go through autolytic cleavage and cleave downstream effector caspases (e.g., caspase-3) (Shalini et al., 2015).”
BackgroundChina Brain Project: Basic Neuroscience, Brain Diseases, and Brain-Inspired Computing
Poo, M.-M., Du, J.-L., Ip, N. Y., Xiong, Z.-Q., Xu, B., & Tan, T. (2016) · Neuron · doi:10.1016/j.neuron.2016.10.050 · Cited by 271
“…intervention of disease progression, particularly for neurodegenerative disorders such as AD, is a promising front of future drug development, as suggested by the recent progress associated with the clinical trials using antibody therapy of prodromal or mild AD (Sevigny et al., 2016).”
BackgroundLi, S., & Selkoe, D. J. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15007 · Cited by 263
“…with these findings, Aβ immunotherapy has been confirmed to protect against the cognitive deficits observed in APP transgenic mice (Carrera et al., 2015; Hartman et al., 2005; Sevigny et al., 2016) and prevent the LTP impairment induced by Aβ oligomers (Klyubin et al., 2005, 2008; Li et al., 2018).”
T cell responses in the central nervous system
Korn, T., & Kallies, A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.144 · Cited by 268
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266
“The Clinical Dementia RatingSum of Boxes (CDR-SB) and MMSE scores were delayed by aducanumab treatment, indicating a positive effect on cognition and clinical progression [41].”
MethodResultMultispecific drugs herald a new era of biopharmaceutical innovation
Deshaies, R. J. (2020) · Nature · doi:10.1038/s41586-020-2168-1 · Cited by 262
Cummings, J. (2023) · Drugs · doi:10.1007/s40265-023-01858-9 · Cited by 241
“Aducanumab produced dose- and time-dependent reduction of amyloid plaque in a Phase 1 trial (PRIME) and was then assessed in two Phase 3 trials (EMERGE, ENGAGE) [4, 9].”
BackgroundMethodInfluentialLymphatic drainage system of the brain: A novel target for intervention of neurological diseases
Sun, B.-L., Wang, L.-H., Yang, T., Sun, J.-Y., Mao, L.-L., Yang, M.-F., Yuan, H., Colvin, R. A., & Yang, X.-Y. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.08.007 · Cited by 255
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
Cummings, J. L., Cohen, S., van Dyck, C. H., Brody, M., Curtis, C., Cho, W., Ward, M., Friesenhahn, M., Rabe, C., Brunstein, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005550 · Cited by 252
Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions
Abeysinghe, A. A. D. T., Deshapriya, R. D. U. S., & Udawatte, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117996 · Cited by 237
Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies
Chen, Y., Fu, A. K. Y., & Ip, N. Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.006 · Cited by 258
“…IgG1monoclonal antibody derived from a cognitively normal donor that preferentially binds to Aβ aggregates in the parenchymal tissue, and exhibits a dose- and time-dependent effect on the removal of amyloid from the patient's brain while slowing the rate of cognitive decline (Sevigny et al., 2016).”
BackgroundLanctôt, K. L., Lindsay, M. P., Smith, E. E., Sahlas, D. J., Foley, N., Gubitz, G., Austin, M., Ball, K., Bhogal, S., Blake, T., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493019847334 · Cited by 230
“Other developments in the diagnosis and treatment of dementia include monoclonal antibodies, such as aducanumab, which selectively targets and binds aggregated amyloid-b (Ab) plaques, and has been shown to reduce their concentrations in the brains of persons with mild Alzheimer’s disease.(106) In the future, if more s…”
BackgroundSingh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 228
Brain borders at the central stage of neuroimmunology
Rustenhoven, J., & Kipnis, J. (2022) · Nature · doi:10.1038/s41586-022-05474-7 · Cited by 253
The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice
Banerjee, G., Carare, R., Cordonnier, C., Greenberg, S. M., Schneider, J. A., Smith, E. E., Buchem, M. V., Grond, J. V. D., Verbeek, M. M., & Werring, D. J. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314697 · Cited by 240
Batista, A. F., Forny‐Germano, L., Clarke, J. R., Lyra e Silva, N. M., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246
“It was recently reported that aducanumab, a monoclonal antibody against Aβ, decreases Aβ plaque density and slows cognitive decline in AD patients [88].”
BackgroundUltra–Low-Dose18F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs
Chen, K. T., Gong, E., de Carvalho Macruz, F. B., Xu, J., Boumis, A., Khalighi, M., Poston, K. L., Sha, S. J., Greicius, M. D., Mormino, E., et al. (2019) · Radiology · doi:10.1148/radiol.2018180940 · Cited by 248
Erratum: Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.158 · Cited by 248
The “rights” of precision drug development for Alzheimer’s disease
Cummings, J., Feldman, H. H., & Scheltens, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0529-5 · Cited by 238
MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease
Balusu, S., Horré, K., Thrupp, N., Craessaerts, K., Snellinx, A., Serneels, L., T’Syen, D., Chrysidou, I., Arranz, A. M., Sierksma, A., et al. (2023) · Science · doi:10.1126/science.abp9556 · Cited by 230
Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches
Hussain, R., Zubair, H., Pursell, S., & Shahab, M. (2018) · Brain Sciences · doi:10.3390/brainsci8090177 · Cited by 229
Alexander, G. C., Emerson, S., & Kesselheim, A. S. (2021) · JAMA · doi:10.1001/jama.2021.3854 · Cited by 240
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
“This study showed a dose-time-dependent reduction in Aβ plaques and an improvement in clinical manifestations of AD, as assessed by the Clinical Dementia RatingSum of Boxes (CDR-SB) and Mini Mental State Examination (MMSE) scores for the highest dose [20].”
MethodEide, P. K., & Ringstad, G. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18760974 · Cited by 234
“In AD, several attempts at therapeutically targeting pathological Ab aggregates have been unsuccessful, perhaps due to inability of monoclonal antibodies to engage their target outside the blood–brain barrier.(74) In future developments, drugs with the ability to both target disease and enter the extravascular compart…”
BackgroundIn vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease
Watt, G., & Karl, T. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00020 · Cited by 227
“A recent study investigating an antibody based immunotherapy for Aβ found promising results in phase I and phase II trials but this therapy is yet to undergo phase III clinical trials (Sevigny et al., 2016).”
BackgroundMethodStop Alzheimer’s before it starts
McDade, E., & Bateman, R. J. (2017) · Nature · doi:10.1038/547153a · Cited by 230
A review on advances of treatment modalities for Alzheimer's disease
Se Thoe, E., Fauzi, A., Tang, Y. Q., Chamyuang, S., & Chia, A. Y. Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119129 · Cited by 219
Prevention of dementia in an ageing world: Evidence and biological rationale
Grande, G., Qiu, C., & Fratiglioni, L. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101045 · Cited by 229
“Over the past four decades, numerous clinical trials have failed to identify any drugs that could cure dementia or AD, or even substantially modify the disease process (Cummings et al., 2019; Panza et al., 2019; Sevigny et al., 2016).”
BackgroundMolecular hybridization: a powerful tool for multitarget drug discovery
de Sena Murteira Pinheiro, P., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 204
“After two decades of disappointment, a breakthrough came with the approval of the anti-amyloid antibodies aducanumab in 2021 [104,105] and lecanemab in 2023 [106].”
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226
Affibody molecules as engineered protein drugs
Frejd, F. Y., & Kim, K.-T. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.35 · Cited by 225
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00838-z · Cited by 224
“Following a promising phase 1B trial [3], the sponsor (Biogen) implemented two phase 3 studies—EMERGE and ENGAGE.”
MethodSelf-citationBiomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
Lewcock, J. W., Schlepckow, K., Di Paolo, G., Tahirovic, S., Monroe, K. M., & Haass, C. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.029 · Cited by 221
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Dysregulation of neuronal calcium homeostasis in Alzheimer's disease – A therapeutic opportunity?
Popugaeva, E., Pchitskaya, E., & Bezprozvanny, I. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.053 · Cited by 214
“Most drugs developed based on this approach failed to show any potential benefit for patients in clinical trials [6], although some promising trends have been recently reported in the trial of anti-Aβ antibody aducanumab [7].”
BackgroundThe physics of polymer chain-folding
Hu, W. (2018) · Physics Reports · doi:10.1016/j.physrep.2018.04.004 · Cited by 216
Ohta, S., Kikuchi, E., Ishijima, A., Azuma, T., Sakuma, I., & Ito, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-75253-9 · Cited by 207
Recent progress of drug nanoformulations targeting to brain
Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.004 · Cited by 213
Peripheral immune system in aging and Alzheimer’s disease
Cao, W., & Zheng, H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0284-2 · Cited by 214
Mouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
“Aducanumab bound the cerebral Aβ deposits and reduced Aβ burden in a dose-dependent manner when administered to aged Tg2576 and APP23 mice (Sevigny et al., 2016; Uhlmann et al., 2020).”
BackgroundOld Maids: Aging and Its Impact on Microglia Function
Koellhoffer, E., McCullough, L., & Ritzel, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040769 · Cited by 207
“While these results were disappointing, there is renewed hope in the clinical effectiveness of aducanumab, an antibody that selectively targets aggregated Aβ which appears to show promise in preclinical studies and clinical trials [138].”
The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort
Borland, E., Nägga, K., Nilsson, P. M., Minthon, L., Nilsson, E. D., & Palmqvist, S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170203 · Cited by 202
Gao, X.-L., Sui, Y., Liu, S., & Sun, Y.-P. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.255995 · Cited by 211
“…2016) 2016 50.9821 2017 2019 ▂▂▃▃▃ CUMMINGS JL, ALZHEIMERS RES THER (Cummings et al., 2014) 2014 28.8266 2017 2019 ▂▂▃▃▃ SELKOE DJ, EMBO MOL MED (Selkoe and Hardy, 2016) 2016 87.2972 2017 2019 ▂▂▃▃▃ SEVIGNY J, NATURE (Sevigny et al., 2016) 2016 45.5145 2017 2019 ▂▂▃▃▃ Copyright license…”
BackgroundInfluentialNicoll, J. A. R., Buckland, G. R., Harrison, C. H., Page, A., Harris, S., Love, S., Neal, J. W., Holmes, C., & Boche, D. (2019) · Brain · doi:10.1093/brain/awz142 · Cited by 202
“This patchiness of removal has been a recurring phenomenon in subsequent amyloid-b immunotherapy trials (Sperling et al., 2012; Sevigny et al., 2016) and remains unexplained, but could perhaps be due to local alterations in the blood–brain barrier associated with an ageing cerebral vasculature,…”
BackgroundInfluentialKlein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212
Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment
Hane, F. T., Robinson, M., Lee, B. Y., Bai, O., Leonenko, Z., & Albert, M. S. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160907 · Cited by 197
“Although statistically significant results were found, the observed effects were relatively small; further exploration of intranasal insulin therapy and the effects of insulin on AD progression are warranted [118].”
BackgroundResultAlzheimer disease and aducanumab: adjusting our approach
Selkoe, D. J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0205-1 · Cited by 208
Weihofen, A., Liu, Y., Arndt, J. W., Huy, C., Quan, C., Smith, B. A., Baeriswyl, J.-L., Cavegn, N., Senn, L., Su, L., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.016 · Cited by 195
“Based on the hypothesis that some endogenous antibodies could be protective, we identified a panel of α-syn binding antibodies by screening memory human B-cell libraries from healthy elderly individuals with no signs of neurodegenerative disorders (Jelcic et al., 2015; Sevigny et al., 2016).”
BackgroundMethodSelf-citationGyörgy, B., Lööv, C., Zaborowski, M. P., Takeda, S., Kleinstiver, B. P., Commins, C., Kastanenka, K., Mu, D., Volak, A., Giedraitis, V., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.03.007 · Cited by 190
Alzheimer’s Disease, Oligomers, and Inflammation
Forloni, G., & Balducci, C. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170819 · Cited by 194
Aducanumab for Alzheimer’s disease?
Walsh, S., Merrick, R., Milne, R., & Brayne, C. (2021) · BMJ · doi:10.1136/bmj.n1682 · Cited by 159
Chen, L.-L., Fan, Y.-G., Zhao, L.-X., Zhang, Q., & Wang, Z.-Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106301 · Cited by 200
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies
Linse, S., Scheidt, T., Bernfur, K., Vendruscolo, M., Dobson, C. M., Cohen, S. I. A., Sileikis, E., Lundqvist, M., Qian, F., O’Malley, T., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0505-6 · Cited by 201
Self-citationTreatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery
Pardridge, W. M. (2020) · Pharmaceuticals · doi:10.3390/ph13110394 · Cited by 194
“In clinical trials, aducanumab reduces amyloid plaque in AD [22], which is indicative of antibody penetration into the brain.”
BackgroundMethodInfluentialElevated CSF GAP‐43 is Alzheimer's disease specific and associated with tau and amyloid pathology
Sandelius, Å., Portelius, E., Källén, Å., Zetterberg, H., Rot, U., Olsson, B., Toledo, J. B., Shaw, L. M., Lee, V. M. Y., Irwin, D. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.006 · Cited by 189
“Recently, disease-modifying drugs targeting Aβ pathology, such as β-secretase inhibitors and the anti-Aβ antibody aducanumab, have shown promising results [5,6] highlighting an increasing need to correctly identify patients with AD pathology.”
BackgroundThe role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases
DeMaio, A., Mehrotra, S., Sambamurti, K., & Husain, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02605-9 · Cited by 174
“However, the approval of aducanumab has been met with controversy and many questions arose about the efficacy of this drug [173, 282].”
BackgroundApolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease
Liao, F., Yoon, H., & Kim, J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000383 · Cited by 221
“a preliminary finding, anti-amyloid b antibody treatment dramatically decreased amyloid b accumulation and slowed cognitive decline in a clinical trial [2].”
BackgroundToward personalized cognitive diagnostics of at-genetic-risk Alzheimer’s disease
Coughlan, G., Coutrot, A., Khondoker, M., Minihane, A.-M., Spiers, H., & Hornberger, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901600116 · Cited by 180
“A major challenge at this stage, however, is to understand how interindividual and demographic factors affect spatial navigation to identify earliest pathological spatial navigation changes in AD (16 – 19).”
Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.
Filippi, M., Cecchetti, G., Spinelli, E. G., Vezzulli, P., Falini, A., & Agosta, F. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.5205 · Cited by 189
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 221
“Anti-A β immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
BackgroundAmyloid blood biomarker detects Alzheimer's disease
Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708763 · Cited by 185
“…as an initial screening funnel to identify people who should undergo further diagnostics and eventually take part in clinical trials on therapeutics targeting Ab misfolding (Sevigny et al, 2016) might already be an important step forward because subjects with early AD stages are hard to identify.”
BackgroundAckley, S. F., Zimmerman, S. C., Brenowitz, W. D., Tchetgen Tchetgen, E. J., Gold, A. L., Manly, J. J., Mayeda, E. R., Filshtein, T. J., Power, M. C., Elahi, F. M., et al. (2021) · BMJ · doi:10.1136/bmj.n156 · Cited by 174
Alzheimer's and Parkinson's disease therapies in the clinic
Chopade, P., Chopade, N., Zhao, Z., Mitragotri, S., Liao, R., & Chandran Suja, V. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10367 · Cited by 174
Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
“Aducanumab is a monoclonal antibody selective for aggregated forms of Aβ, with demonstrated efficacy in the clearance of brain Aβ plaques.(6) According to the amyloid cascade hypothesis, the extracellular accumulation of Aβ aggregates is the leading cause of synapses dysfunction, neuroinflammation, neuronal loss and i…”
BackgroundMethodInfluentialInformatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives
Romano, J. D., & Tatonetti, N. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00368 · Cited by 175
AI-based differential diagnosis of dementia etiologies on multimodal data
Xue, C., Kowshik, S. S., Lteif, D., Puducheri, S., Jasodanand, V. H., Zhou, O. T., Walia, A. S., Guney, O. B., Zhang, J. D., Poésy, S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03118-z · Cited by 182
Anti-amyloid antibody therapies in Alzheimer's disease
Perneczky, R., Jessen, F., Grimmer, T., Levin, J., Flöel, A., Peters, O., & Froelich, L. (2023) · Brain · doi:10.1093/brain/awad005 · Cited by 182
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
Sardi, S. P., Cedarbaum, J. M., & Brundin, P. (2018) · Movement Disorders · doi:10.1002/mds.27414 · Cited by 170
“Importantly, the reduction of Abeta plaques in Alzheimer’s disease by the antibody aducanumab provides evidence that effective CNS antibody concentrations can be achieved.(19)”
BackgroundResultOuyang, J., Chen, K. T., Gong, E., Pauly, J., & Zaharchuk, G. (2019) · Medical Physics · doi:10.1002/mp.13626 · Cited by 180
Andjelkovic, A. V., Situ, M., Citalan-Madrid, A. F., Stamatovic, S. M., Xiang, J., & Keep, R. F. (2023) · Stroke · doi:10.1161/strokeaha.122.040578 · Cited by 164
Grimm, H. P., Schumacher, V., Schäfer, M., Imhof-Jung, S., Freskgård, P.-O., Brady, K., Hofmann, C., Rüger, P., Schlothauer, T., Göpfert, U., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2261509 · Cited by 169
“9–11–15–42,43 In addition, the targeted endothelial cell receptors typically have vital functions in the homeostasis of their endogenous physiologic substrate in the brain and other tissues that could potentially be disrupted by brain-targeting antibodies.”
Background
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.